Press release
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.
‘A large amount of IITs are oncology trials which generally bear a lot of adverse events (AEs) and serious adverse events (SAEs)’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Many of these events are unrelated to the drug in question. The SAE review process can be a substantial administrative burden for trial sponsors. With our flexible and highly responsive Pharmacovigilance Services we are in a position to take over the entire drug safety reporting for them.’
In addition, ICRC-Weyer is able to handle the reporting of serious adverse drug reactions (ADRs) – adverse events that are directly related to the substance. All events can be transmitted electronically using an E2B*-compliant database.
*Guideline on clinical safety data management by the International Conference on Harmonisation (ICH)
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.
ICRC-Weyer has special expertise in Advanced Therapies, CDISC Data Standards and Medical Review.
Dr Ulrike Treichel
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: ulrike.treichel@icrc-weyer.com
www.icrc-weyer.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials here
News-ID: 262226 • Views: …
More Releases from ICRC-Weyer GmbH
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio.
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted…
More Releases for Weyer
Global Neonatal Incubator Market - AHT, Natus Medical, Weyer GmbH, Fanem
The report that is written on the title Neonatal Incubator Market covers all across the globe, recently added to the repository of Market Research, is titled ‘Global Neonatal Incubator Market 2017’. The research report analyses the historical as well as present performance of the worldwide Neonatal Incubator industry, and makes predictions on the future status of Neonatal Incubator market on the basis of this analysis.
An infant incubator is a…
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio.
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted…
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in…
